Last Updated: 13 January 2025

hc1, a leader in transforming lab data into actionable intelligence to improve patient health outcomes, has successfully raised $6.25 million in funding.
The financing, which comes shortly after the October 2024 acquisition of Accumen, will support the development of enhanced solutions combining hc1’s advanced analytics with Accumen’s expertise to improve healthcare efficiency, patient care, and operational performance.
The funding round was led by Health Cloud Capital, with participation from A1 Health Ventures. Arsenal Capital Partners became part of the investor group through its ownership stake in Accumen.
Patients often face over- or under-testing due to reliance on limited diagnostic snapshots, leading to missed diagnoses and waste in healthcare. This inefficiency contributes to the $760 billion in annual wasted healthcare costs in the United States.
hc1 addresses these gaps by transforming diagnostic labs into strategic assets for healthcare systems. The company’s solutions leverage lab stewardship, advanced analytics, and AI-powered best practices to improve health outcomes, reduce waste, and enhance efficiency.
"Ongoing pressures on healthcare delivery operations and financing require providers, payors, and pharma manufacturers to utilize insights from a massive, growing base of patient data. hc1’s solutions support proactive management of longitudinal patient health, rather than reflexive responses to point-in-time care events. Their technology platform is uniquely positioned as the leader in identifying risk signals and insights in diagnostic lab data. As a result, their clients gain insights that improve patient care while enhancing financial results. hc1 ideally aligns with our strategy to leverage data at scale using advanced data science and expert services to drive sustainable improvements in healthcare delivery."
Jon Phillips, Managing Director of A1 Health Ventures
hc1 plans to use the $6.25 million to launch enhanced solutions that integrate its existing technology with Accumen’s expertise. This initiative focuses on:
In addition, hc1 aims to expand its market reach and refine its AI-driven analytics platform. The company’s future growth targets include improving efficiency across healthcare systems and boosting the profitability of lab outreach programs.
“Having these esteemed investors join Health Cloud Capital alongside our Accumen acquisition provides a resounding endorsement for hc1’s strategy and team. Beyond capital, A1 Health Ventures and Arsenal Capital Partners bring unique access to industry thought leaders, talent, and health system partners to unlock the value of actionable lab data.”
Bradley Bostic, hc1’s Founder and CEO
hc1, founded in 2011, is a leader in transforming lab data into actionable intelligence. Headquartered in Indianapolis, hc1 specializes in predictive insights, personalized care, and operational efficiency for healthcare systems. The company has partnered with thousands of health systems and diagnostic labs, supporting nearly 100 million patients annually.
hc1’s innovative platform combines advanced data management, AI-driven analytics, and workflow automation to reveal hidden insights and risks in diagnostic data.
These capabilities enable healthcare providers to make informed decisions that improve patient care and financial performance.
The success of hc1’s latest funding round is a testament to the confidence its investors have in the company’s mission and innovative approach. The funding was backed by a group of prominent organizations with deep expertise in healthcare technology and financial growth, each bringing unique resources and insights to help hc1 achieve its goals.